Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy
Launched by CHINESE UNIVERSITY OF HONG KONG · Nov 9, 2010
Trial Information
Current as of May 08, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • able 18 years of age
- • undergone primary radiotherapy or chemoradiotherapy as the treatment
- • are expected to complete the 12 month follow-up
- Exclusion Criteria:
- • prior history of head and neck surgery except biopsies of the NP or the neck nodes
- • previous history or having a concurrent neoplasm other than NPC
- • other severe medical problems that might contribute to dysphagia, e.g. cerebral vascular accident, neuromuscular diseases, respiratory diseases that may cause dysphagia
- • present contraindications for the use of electrical stimulation which include pregnancy, pacemaker, other implanted electrodes or significant reflux
- • non-oral feeding is contemplated in prior to treatment
- • inability to complete the assessment including cognitive impairment
- • of a low life expectancy related to NPC or other illnesses
- • history of dysphagia prior to radiotherapy or chemoradiotherapy
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shatin, New Territories, Hong Kong
Kowloon, , Hong Kong
Patients applied
Trial Officials
Michael Tong
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials